Christopher Charles Khoo

Christopher Charles Khoo

Auto-generated profile, based on publicly available information

Christopher Charles Khoo

Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2019 in BJU International
Verified
Journal Article
Closed access
PDF file
CKChristopher C. Khoo
Christopher C. Khoo
DEDavid Eldred‐Evans
David Eldred‐Evans
MPMax Peters
Max Peters
MTMariana Bertoncelli Tanaka
Mariana Bertoncelli Tanaka
MNMohamed Noureldin
Mohamed Noureldin
HAHashim Uddin Ahmed
Hashim Uddin Ahmed

1 June 2020 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
CKChristopher C. Khoo
Christopher C. Khoo
SMSaiful Miah
Saiful Miah
MCMartin J. Connor
Martin J. Connor
JTJoseph Tam
Joseph Tam
MWMathias Winkler
Mathias Winkler
TSTaimur T. Shah
Taimur T. Shah
Although radiotherapy to the prostate for cancer is effective, recurrence occurs in 10–15% within 5 years. Traditional salvage treatments for men with radiorecurrent prostate cancer comprise of watchful waiting (WW) with or without androgen deprivation therapy (ADT) or radical prostatectomy (RP). Neither strategy provides ideal therapeutic ratios. Salvage focal ablation is an emerging option. We performed a systematic review of the Medline and Embase databases for studies reporting outcomes of focal salvage brachytherapy (sBT), cryotherapy (sCT) or high-intensity focused ultrasound (sHIFU) for radiorecurrent prostate cancer (conception to April 2019). Results were screened for inclusion against predetermined eligibility criteria. Certain data were extracted, including rates of biochemical disease-free survival (BDFS), metastasis, conversion to second-line therapies and adverse events. Of a total 134 articles returned from the search, 15 studies (14 case series and 1 comparative study) reported outcomes after focal sBT [5], sCT [7] and sHIFU [3]. Cohort size varied depending on intervention, with eligible studies of sBT being small case series. Median follow-up ranged from 10 to 56 months. Although pre-salvage demographics were similar [median age range, 61–75 years; prostate-specific antigen (PSA) range, 2.8–5.5 ng/mL], there was heterogeneity in patient selection, individual treatment protocols and outcome reporting. At 3 years, BDFS ranged from 61% to 71.4% after sBT, 48.1–72.4% after sCT and 48% after sHIFU. Only studies of sCT reported 5-year BDFS, which ranged from 46.5% to 54.4%. Rates of metastasis were low after all salvage modalities, as were conversion to second-line therapies (although this was poorly reported). Grade 3 adverse events were rare. This systematic review indicates that salvage focal ablation of radiorecurrent prostate cancer provides acceptable oncological outcomes and is well tolerated. Unfortunately, there is heterogeneity in the study design of existing evidence. Level 1 research comparing salvage focal therapies to existing whole-gland strategies is needed to further establish the role of these promising treatments.

18 November 2021 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
TTTharu Tharakan
Tharu Tharakan
CKChristopher C. Khoo
Christopher C. Khoo
AGAleksander Giwercman
Aleksander Giwercman
CJChanna N Jayasena
Channa N Jayasena
NSNikolaos Sofikitis
Nikolaos Sofikitis
SMSuks Minhas
Suks Minhas

13 September 2023 in European Urology Focus
Verified
Journal Article
Closed access
CKChristopher C. Khoo
Christopher C. Khoo
ACAxel Alberto Cayetano-Alcaraz
Axel Alberto Cayetano-Alcaraz
RRRazi Rashid
Razi Rashid
TTTharu Tharakan
Tharu Tharakan
TYTet Yap
Tet Yap
SMSuks Minhas
Suks Minhas

1 December 2021 in Journal of Endourology
Verified
Journal Article
Closed access
CKChristopher Charles Khoo
Christopher Charles Khoo
CHCarmen Ho
Carmen Ho
VPVarun Palaniappan
Varun Palaniappan
ATAndrew Ting
Andrew Ting
LFLuke Forster
Luke Forster
RDRanan Dasgupta
Ranan Dasgupta
Purpose: Patients with chronic ureteric obstruction (CUO) are traditionally managed with polymer stents/nephrostomy. However, these are prone to failure and require regular exchange. This study evaluates efficacy of Allium® URS, Memokath™-051 and Resonance® metallic ureteric stents in managing patients with CUO. Method: Following institutional approval, operating theatre records were reviewed to identify patients with CUO managed with either Allium® URS, Memokath™-051 or Resonance® metallic ureteric stents (September 2015/July 2020). Baseline patient variables (age, gender, underlying aetiology, ASA) and stricture characteristics (length, level, continuity) were extracted. Intra- and post-operative clinical and radiological assessments at 6 weeks, 3 months and then every 6 months, as well as any emergency attendances, were reviewed. The primary outcome was duration of functional stent survival. Secondary outcomes included intra-operative placement success and, as anestimate of renal function, mean serum creatinine over time. Results: 129 stent insertion episodes (SIEs) (Allium® URS: 23, Memokath™-051: 48, Resonance®: 58) occurred in 76 patients (Allium® URS: 16; Memokath™-051: 31; Resonance®: 29). Kaplan-Meier estimates demonstrated that Resonance® provided superior functional stent survival. Overall median actual functional stent follow-up was 11.4 months for Allium® URS, 5.5 months for Memokath™-051 and 11.7 months for Resonance®. 47.8% of Allium® URS (11/23), 64.6% of Memokath™-051 (31/48) and 19% of Resonance® SIEs (11/58) failed. No Resonance® SIEs for benign indication ended in failure. Intra-operative placement success was high (Allium® URS: 95.7%; Memokath™-051 and Resonance®: both 100%). In the first year following SIE, creatinine ranged from +21.3% to +46.7% for Allium® URS, -7.8% to +8.9% for Memokath™-051, and -9.4% to +27.3% for Resonance®. Conclusions: Allium® URS, Memokath™-051 and Resonance® metallic ureteric stents are all viable management options of CUO. In this cohort, Resonance® provided superior functional stent survival. Prospective large-scale comparisons with long-term follow-up are needed to help inform stent choice dependant on individual patient and stricture characteristics.

24 November 2016 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
CKChristopher Charles Khoo
Christopher Charles Khoo
NANikhil Ahluwalia
Nikhil Ahluwalia
JGJan Grace
Jan Grace
ASArun Sahai
Arun Sahai
A 37-year-old woman receiving in vitro fertilisation (IVF) treatment presented with lethargy, fevers and anuria. Her background included complex surgically managed Crohn's disease and mild right-sided hydronephrosis (with no evidence of obstruction on MAG3 renogram). On examination, she had a distended abdomen with generalised tenderness. Blood tests revealed an acute kidney injury and confirmed sepsis. She was found to have bilateral ureteric obstruction with worsening of the right-sided hydronephrosis and new-onset left-sided hydronephrosis secondary to bilateral ovarian masses, diagnosed as mild ovarian hyperstimulation syndrome (OHSS). She was initially managed with fluid resuscitation, bilateral nephrostomies, antibiotics and supportive management of mild OHSS. She made a good recovery and was discharged after placement of antegrade stents and removal of nephrostomies. On follow-up, following resolution of ovarian hyperstimulation, she has been diagnosed with a right-sided distal ureteric stricture and is awaiting reconstruction. Her left ureteric stent has been removed.